Real-World Experience of Dupilumab Treatment for Patients with COPD – A Single Center Prospective Study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This prospective study evaluates dupilumab’s effectiveness in COPD patients, highlighting reduced exacerbations and improved patient satisfaction.

Dupilumab treatment lowered exacerbation rates significantly from 3.47 to 1.55 annually, indicating effectiveness.
Among 23 COPD patients, median treatment duration was 320 days, and 61% expressed satisfaction with dupilumab.
Patient reported outcomes showed that 30% reported marked improvements using the GETE tool, underscoring treatment benefits.
Despite a reduction in exacerbations, challenges included treatment costs (48%) and the need for repeated injections (21%).

Freund et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This prospective study evaluates dupilumab’s effectiveness in COPD patients, highlighting reduced exacerbations and improved patient satisfaction.